Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial.
Emmanuelle CambauIsabelle Durand-ZaleskiStéphane BretagneChristian Brun-BuissonCatherine CordonnierXavier DuvalStéphanie HerweghJulien PottecherRené CourcolSylvie Bastuji-Garinnull nullPublished in: Intensive care medicine (2017)
Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358.
Keyphrases
- open label
- healthcare
- phase iii
- phase ii
- study protocol
- clinical trial
- phase ii study
- placebo controlled
- double blind
- gram negative
- early onset
- palliative care
- randomized controlled trial
- quality improvement
- molecular dynamics
- affordable care act
- antimicrobial resistance
- pain management
- drug induced
- social media
- multidrug resistant
- health information
- chronic pain
- rectal cancer